LOGO
LOGO

Clinical Trial Calendar

Results Date
Company Name
Ticker
Event
Indication
Outcome
Mid 2026
Avalo Therapeutics, Inc.
AVTX
Topline data from Phase 2 trial of AVTX-009 (LOTUS)
Hidradenitis suppurativa
Positive results reported from its Phase 2 LOTUS trial of abdakibart (AVTX-009) in adults with moderate to severe hidradenitis suppurativa on 5th May 2026.
Mid 2026
Karyopharm Therapeutics Inc.
KPTI
Top-line data from Phase 3 trial of selinexor (XPORT-EC-042)
TP53 wild-type endometrial cancer
Trial misses endpoints; reported on July 30, 2026
Mid 2026
Kezar Life Sciences, Inc.
KZR
Topline Phase 2b data of zetomipzomib (PALIZADE)
Active lupus nephritis
Mid 2026
Moleculin Biotech Inc
MBRX
Interim data from Phase 2/3 trial of Annamycin in combination with cytarabine (MIRACLE)
Relapsed or refractory acute myeloid leukemia
Positive data reported on July 31, 2026
Mid 2026
ArriVent Biopharma, Inc.
AVBP
Topline data from Phase 3 trial of Firmonertinib (FURVENT )
Non-small cell lung cancer (NSCLC) patients whose tumors contain EGFR exon 20 insertion mutations
Mid 2026
EyePoint, Inc.
EYPT
Topline data from phase III trial of DURAVYU (LUGANO)
Wet age-related macular degeneration
Phase 3 LUGANO trial of DURAVYU in wet age-related macular degeneration did not achieve its primary endpoint in the full dataset, according to the company. The data reported on 17th Aug. 2026.
Mid 2026
Pliant Therapeutics, Inc.
PLRX
Data from Phase 2b trial of bexotegrast (BEACON-IPF)
Idiopathic pulmonary fibrosis (IPF).
Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis discontinued following recommendations from an independent Data Safety Monitoring Board. The company announced the decision on Mar. 3, 2025.
Mid 2026
MetaVia Inc.
MTVA
Interim data readout from Part 3 of Phase 1 trial of DA-1726
Obesity
Study shows progressive weight loss of up to 9.1% at the 48 mg dose level; reported on June 8, 2026
Mid 2026
Spyre Therapeutics, Inc.
SYRE
Part ATopline results from Phase 2 trial of SPY002 (SKYLINE)
moderately to severely active UC
SPY002 meets primary endpoint; reported on June 15, 2026
Mid 2026
ACADIA Pharmaceuticals Inc
ACAD
Topline results from Phase 2 study of ACP-204 (RADIANT)
Alzheimer’s disease psychosis
Mid 2026
Repare Therapeutics Inc.
RPTX
Final readout of proof-of-concept from Phase 1 trial of RP-1664 in adult and adolescent (LIONS)
TRIM37-high solid tumors
Mid 2026
Alto Neuroscience, Inc.
ANRO
Topline data from Phase 2b trial of ALTO-300
Major depressive disorder
Mid 2026
MediWound Ltd.
MDWD
Interim analysis from Phase III trial of EscharEx (VALUE)
Venous leg ulcers
Mid 2026
Sionna Therapeutics, Inc.
SION
Topline data from Phase 2a Proof-of-Concept trial of NBD1 stabilizer in combination with standard of care
Cystic fibrosis
Mid 2026
Sionna Therapeutics, Inc.
SION
Topline data from Phase 2a MAD trial of NBD1 stabilizer with complementary modulator in healthy volunteers
Cystic fibrosis
Mid 2026
Rocket Pharmaceuticals, Inc.
RCKT
Data readout from Phase 2 study of RP-A501
Danon disease
Mid 2026
Aura Biosciences, Inc.
AURA
Initial three-month data from Phase 1b/2 Trial of Bel-sar
Non-Muscle-Invasive Bladder Cancer
Mid 2026
AbCellera Biologics Inc
ABCL
Initial safety and efficacy data from Phase 1 trial of ABCL635
Moderate-to-severe vasomotor symptoms (VMS) associated with menopause
Positive interim reported from Phase 1 trial of ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause on 11th May 2026.
Mid 2026
Sionna Therapeutics, Inc.
SION
Topline data from Phase 1 trial of SION-451 in combination with SION-2222
Paradigm for cystic fibrosis
Mid 2026
AbCellera Biologics Inc
ABCL
Data from Phase 1 trial of ABCL575
Moderate-to-severe atopic dermatitis
Mid 2026
Biodexa Pharmaceuticals Plc
BDRX
Read out from Phase 2 study of eRapa
Non-muscle Invasive Bladder Cancer or NMIBC
Mid 2026
Karyopharm Therapeutics Inc.
KPTI
Top-line data from Phase 3 trial of selinexor (XPORT-EC-042)
TP53 wild-type advanced or recurrent endometrial cancer
Results from its Phase 3 XPORT-EC-042 trial of selinexor in adult patients with TP53 wild-type advanced or recurrent endometrial cancer did not meet its primary endpoint, according to the company. The data reported on 30th July 2026.
Mid 2026
Atea Pharmaceuticals, Inc.
AVIR
Topline results from Phase 3 trial of bemnifosbuvir in combination with ruzasvir (C-BEYOND)
Hepatitis C Virus (HCV) treatment-Naïve Patients in US and Canada
Trial meets endpoints; reported on July 28, 2026
Mid 2026
Benitec Biopharma
BNTC
Interim results from Cohort 2 of Phase 1b/2a trial of BB-301
Oculopharyngeal Muscular Dystrophy-related Dysphagia
Positive interim results from Cohort 2 of Phase 1b/2a trial of BB-301 in Oculopharyngeal Muscular Dystrophy-related Dysphagia on 15th May 2026.
Mid 2026
Coherus Oncology, Inc.
CHRS
First data readout from Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab
1st-line hepatocellular carcinoma (HCC).

Only seeing part of the calendar?

Get our FREE PDF — "The Next 30 Days Of FDA Events" — covering upcoming clinical trial readouts and regulatory dates, no subscription required.

Send Me The Guide →
Buy this Content
Editors Pick
tesla 24082026 lt

Tesla Recalls 3 Mln Cars In China Over Hidden Door Handles; Shares Drop

August 24, 2026 09:51 ET
wallmart 20082026 lt

Walmart Stock Drops On Weak Q2 Profit, Slower U.S. Comps Growth, Despite Positive Outlook

August 20, 2026 08:43 ET
targetcorp1 19082026 lt

Target Lifts FY26 Outlook After Q2 Profit Growth On Tariff Benefit, Comps

August 19, 2026 08:30 ET
homedepot 18082026 lt

Home Depot Q2 Results Rise, Backs FY26 View; Expands Express Delivery

August 18, 2026 09:36 ET
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap